SOQUINOLOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H26N2O3
Molecular Weight	306.3999
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)NCC(O)COC1=C2CCN(CC2=CC=C1)C=O

InChI

InChIKey=GMJHUSJLZXFFQJ-UHFFFAOYSA-N

InChI=1S/C17H26N2O3/c1-17(2,3)18-9-14(21)11-22-16-6-4-5-13-10-19(12-20)8-7-15(13)16/h4-6,12,14,18,21H,7-11H2,1-3H3

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800000152 | https://www.ncbi.nlm.nih.gov/pubmed/2906243

Soquinolol [WE 704] is a β-blocker that was under clinical development for the treatment of heart failure, but this research was discontinued. Soquinolol is a highly potent non-subtype-selective beta-adrenergic receptor blocker, which is devoid of any intrinsic sympathomimetic activity. Its local anaesthetic activity (membrane stabilizing effect) is very weak. It also shows good enteral efficacy and long duration of action. In binding studies with heart (Ki beta 1 = 3.25 nmol/l) and lung membranes (Ki beta 2 = 0.85 nmol/l) its binding profile was found to be similar to that of propranolol.

Approval Year

PubMed

Title	Date	PubMed
Lead-induced cell signaling cascades in GT1-7 cells.	2003-07-15	12832008
Immune function, mitogenicity, and angiogenic growth factor concentrations in lean and obese rodent sera: implications in obesity-related prostate tumor biology.	2003	14663468
Cultured gill epithelia from freshwater tilapia (Oreochromis niloticus): effect of cortisol and homologous serum supplements from stressed and unstressed fish.	2002-11-01	12422270
Differential effects of transforming growth factor-beta2 on corneal endothelial cell proliferation-A role of serum factors.	2002-07	12123637

Patents

Sample Use Guides

In Vivo Use Guide

In the conscious dog soquinolol's beta 1-adrenergic blocking activity (ED 50%) on intravenous injection (5.5 ug/kg) and oral administration (5.8 ug/kg) is about twice as great as that of pindolol and 19 times (i.v.) or 138 times (p.o.) greater than that of propranolol.

Route of Administration: Other

In Vitro Use Guide

In binding studies with heart (Ki beta 1 = 3.25 nmol/l) and lung membranes (Ki beta 2 = 0.85 nmol/l) Soquinolol's binding profile was found to be similar to that of propranolol. Soquinolol inhibits the isoprenaline-induced tachycardia (EC50% = 48 ug/l) in the guinea-pig Langendorff heart in vitro.

Name

Type

Language

Soquinolol [WHO-DD]

Preferred Name

English

SOQUINOLOL

Official Name

English

soquinolol [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29576